Fluconazole and itraconazole susceptibility ofclinical isolates of Cryptococcus neoformans at a tertiary care centre in India: a need for care | Zendy

Kausik Datta | Zendy; Neena Jain | Zendy; Sumita Sethi | Zendy; A Rattan | Zendy; Arturo Casadevall | Zendy; U. Banerjee | Zendy

Open Access

Fluconazole and itraconazole susceptibility ofclinical isolates of Cryptococcus neoformans at a tertiary care centre in India: a need for care

Author(s) -

Kausik Datta,

Neena Jain,

Sumita Sethi,

A Rattan,

Arturo Casadevall,

U. Banerjee

Publication year - 2003

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkg399

Subject(s) - itraconazole , fluconazole , cryptococcus neoformans , azole , cryptococcosis , microbiology and biotechnology , minimum inhibitory concentration , medicine , biology , antifungal , antibiotics

In cryptococcosis, fluconazole is a standard prophylactic, therapeutic and maintenance option, particularly in the expanding HIV/AIDS group. However, its excessive use may lead to resistance in Cryptococcus neoformans. Variations in clinical response to fluconazole have already been noted elsewhere, and cases of post-therapy relapse are not uncommon. To assess azole antifungal susceptibility profiles of clinical cryptococcal isolates in India, the All India Institute of Medical Sciences (AIIMS) has recently initiated preliminary studies using NCCLS M27-A.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research